Oral weight-management medication comparison

Orforglipron vs Contrave: Foundayo GLP-1 pill or naltrexone/bupropion?

Compare Foundayo/orforglipron and Contrave by chronic weight-management label fit, oral routine, GLP-1, mental-health, opioid, seizure, blood-pressure, pregnancy, cost, and seller-safety questions.

Educational guideUpdated July 10, 2026

A safer Foundayo vs Contrave decision path

Confirm the exact product: FDA-approved Foundayo/orforglipron, branded Contrave extended release, separate naltrexone or bupropion, another labeled medicine, or an unsafe seller product using familiar names.

Match the goal and patient to each current label rather than assuming that two oral weight-management medicines have the same mechanism, contraindications, evidence, or follow-up plan.

Screen product-specific risks before convenience or price: GLP-1 thyroid, gastrointestinal, pancreatitis, gallbladder, kidney, glucose, pregnancy, oral-contraceptive, and procedure questions versus Contrave mood, suicide-risk, seizure, eating-disorder, opioid, blood-pressure, liver, kidney, pregnancy, and interaction questions.

Compare the real care model: gastrointestinal, hydration, glucose, and procedure support for Foundayo versus mental-health, blood-pressure, opioid and medication reconciliation, and seizure-risk monitoring for Contrave.

Do not copy a dose-conversion chart, split or crush extended-release tablets, stack either medicine with another weight-loss drug, or buy “generic Foundayo” or Contrave-like ingredient bundles without legitimate prescribing and dispensing.

Direct answer

Foundayo (orforglipron) and Contrave (naltrexone/bupropion extended release) are oral prescription medicines used for chronic weight management in eligible patients, but they are not interchangeable. Foundayo is a non-peptide GLP-1 receptor agonist. Contrave combines an opioid antagonist with bupropion and has different boxed-warning, seizure, opioid, blood-pressure, mental-health, and interaction concerns. A clinician should compare labeled-use fit, thyroid and gastrointestinal history, pancreatitis and gallbladder risk, kidney function and hydration, diabetes medicines, mood or suicidal-thought history, seizure and eating-disorder history, opioid exposure, blood pressure, pregnancy plans, interactions, cost, and follow-up. There is no label-backed dose conversion or universal winner, and patients should not combine or switch these medicines using an online protocol.

Mechanism and product identity

Foundayo is an oral GLP-1; Contrave combines naltrexone and bupropion

Foundayo contains orforglipron, a small-molecule GLP-1 receptor agonist taken as a daily tablet. Contrave is an extended-release tablet containing naltrexone, an opioid antagonist, and bupropion, an antidepressant also used in other products. Both labels include chronic weight-management pathways, but a shared oral route does not make the products, mechanisms, evidence, contraindications, side effects, or monitoring interchangeable. Separate naltrexone and bupropion prescriptions are not automatically equivalent to branded Contrave, and orforglipron is not semaglutide, tirzepatide, retatrutide, or a peptide supplement.

Foundayo review centers on GLP-1 label fit, thyroid C-cell tumor warning history, pancreatitis or gallbladder history, severe gastrointestinal symptoms, dehydration and kidney risk, diabetes medicines, diabetic retinopathy, pregnancy, oral contraception, and planned anesthesia or deep sedation.
Contrave review centers on mood or suicidal thoughts, seizure and eating-disorder history, opioid use or withdrawal, uncontrolled blood pressure, abrupt alcohol or sedative changes, MAOI and other bupropion exposure, liver or kidney function, pregnancy, and interacting medicines.
Peptide12 does not list Foundayo or Contrave in its current treatment catalog; this page is decision support, not an availability promise or a recommendation for either medicine.

Choosing a discussion

Health history, opioid exposure, and follow-up capacity can change the starting conversation

A clinician may discuss Foundayo when a GLP-1 treatment model and daily oral routine fit the patient’s diagnosis, contraindications, access, and follow-up needs. Contrave may be discussed when its labeled pathway fits and mental-health, seizure, eating-disorder, opioid, blood-pressure, liver, kidney, pregnancy, and interaction risks can be managed. Neither medicine is automatically safer because it is a pill. Results from separate trials should not be converted into a head-to-head ranking, and convenience should not outrank contraindications or the ability to complete monitoring.

Foundayo may require extra planning around severe nausea, vomiting or diarrhea, dehydration, kidney concerns, insulin or sulfonylurea use, diabetic eye disease, oral contraceptives, pregnancy plans, prior pancreatitis or gallbladder disease, and procedures involving anesthesia or deep sedation.
Contrave is contraindicated in several settings that include uncontrolled hypertension, seizure disorder, current or prior bulimia or anorexia nervosa, chronic opioid use or acute opioid withdrawal, use of another bupropion-containing product, and recent MAOI use; the current label should guide the complete screen.
Cost comparison should include the exact product, prescriber review, legitimate pharmacy dispensing, records or labs when relevant, blood-pressure or mental-health follow-up, symptom support, refill reassessment, and a documented stopping or maintenance plan.

Side effects and urgent symptoms

The most important monitoring questions are different

Foundayo’s label emphasizes gastrointestinal effects such as nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain, plus serious warnings and precautions involving thyroid C-cell tumor risk, pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury, hypoglycemia with certain diabetes medicines, allergy, gallbladder disease, diabetic retinopathy, aspiration around anesthesia, and oral-contraceptive absorption. Contrave commonly causes nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea, while its label also requires attention to suicidal thoughts or behavior, seizure risk, blood-pressure and heart-rate increases, opioid blockade or withdrawal, liver injury, angle-closure glaucoma, low blood sugar in patients using diabetes medicines, and serious allergic reactions.

Severe persistent abdominal pain, repeated vomiting, inability to keep fluids down, jaundice, facial or throat swelling, fainting, severe low-blood-sugar symptoms, sudden vision changes, or a neck mass need prompt medical guidance during Foundayo treatment.
A seizure, suicidal thoughts, severe mood or behavior change, opioid-withdrawal symptoms, severe allergic symptoms, eye pain or abrupt vision change, jaundice, fainting, or concerning blood-pressure or heart symptoms need prompt evaluation during Contrave treatment.
Medication reconciliation should include insulin, sulfonylureas, oral contraceptives, opioids, tramadol, buprenorphine, methadone, antidepressants, MAOIs, stimulants, decongestants, antiseizure or migraine medicines, sedatives, alcohol, blood-pressure medicines, supplements, and every other weight-management product.

Combining, pregnancy, and online access

Opioid and seizure screening plus no-stack boundaries are central—not optional checkout steps

Contrave can interfere with opioid medicines and can precipitate withdrawal in an opioid-dependent patient; opioid timing and pain-management planning belong with the prescriber and the clinician managing those medicines. Foundayo also should not be treated as a casual preconception or pregnancy weight-loss product, and its label includes pregnancy and oral-contraceptive counseling. Contrave should be discontinued when pregnancy is recognized under clinician guidance because weight loss offers no benefit during pregnancy and may cause fetal harm. A social-media Foundayo-plus-Contrave stack, a switch based on a milligram chart, or a Contrave-like bundle of separate ingredients is not a safe substitute for coordinated care.

Patients should disclose every opioid, opioid-use-disorder medicine, planned surgery, dental procedure, pain-care need, alcohol or sedative change, seizure history, pregnancy plan, and mental-health concern before Contrave is considered.
Avoid “generic Foundayo,” compounded or research-use orforglipron, unlabeled GLP-1 tablets, and sellers that imply a compounded product is FDA-approved Foundayo. Compounded medicines are not FDA-approved finished drug products.
Avoid automatic Contrave approval without blood-pressure, mood, suicide-risk, seizure, eating-disorder, opioid, alcohol or sedative, liver, kidney, pregnancy, glaucoma, MAOI, and medication review—or sellers that bypass legitimate prescriptions and pharmacies.

Patient safety checklist

Questions to ask before choosing orforglipron or Contrave

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Which exact product is being discussed: Foundayo/orforglipron, branded Contrave extended release, separate naltrexone or bupropion, another FDA-approved medicine, or a seller product using a misleading name?

✓

Does the labeled-use pathway fit my age, weight-related conditions, treatment goals, prior response, side effects, pregnancy context, and ability to complete follow-up?

✓

Have medullary thyroid carcinoma or MEN 2 history, pancreatitis or gallbladder disease, severe GI symptoms, kidney or dehydration risk, diabetes medicines, diabetic eye disease, blood pressure, mood or suicidal thoughts, seizure or eating-disorder history, opioid exposure, liver disease, glaucoma, pregnancy, breastfeeding, contraception, and planned procedures been reviewed?

✓

Do I use insulin, a sulfonylurea, an oral contraceptive, an opioid, tramadol, buprenorphine, methadone, an MAOI, another bupropion product, a stimulant, decongestant, antidepressant, antiseizure or migraine medicine, sedative, blood-pressure medicine, alcohol, supplements, or another weight-management product?

✓

If Contrave is considered, who documents blood-pressure checks, mental-health monitoring, seizure and eating-disorder screening, opioid and pain-care planning, interaction review, treatment response, and stopping rules?

✓

If Foundayo is considered, who documents gastrointestinal and hydration support, glucose monitoring when relevant, oral-contraceptive counseling, procedure planning, refill follow-up, and urgent symptoms?

✓

Is the price for the medication alone, or does it include licensed clinician review, legitimate dispensing, records or labs when relevant, follow-up, side-effect support, refill reassessment, and cancellation terms?

✓

Does the seller avoid guaranteed results, generic-Foundayo claims, research products, Contrave-like ingredient shortcuts, automatic approval, copied dose charts, tablet-splitting or crushing hacks, and pressure to prepay before clinician review?

FAQs

Short answers for patients

Is orforglipron the same as Contrave?

No. Foundayo/orforglipron is an oral non-peptide GLP-1 receptor agonist. Contrave is an extended-release tablet combining naltrexone and bupropion. They have different mechanisms, contraindications, warnings, side effects, interactions, and monitoring needs.

Which works better for weight loss, Foundayo or Contrave?

There is no universal winner, and results from separate studies should not be presented as a head-to-head comparison. The appropriate discussion depends on labeled-use fit, health history, opioid exposure, mental-health and seizure risk, other medicines, side-effect tolerance, monitoring capacity, cost, access, and clinician judgment.

Can orforglipron and Contrave be taken together?

Do not create a combination from an online protocol. Combining weight-management medicines can change gastrointestinal symptoms, hydration, glucose, blood pressure, heart rate, sleep, mood, seizure risk, opioid pain-control options, pregnancy safety, and recognition of urgent symptoms. Any proposed combination requires direct, coordinated prescriber review.

Why does opioid use matter with Contrave?

Contrave contains naltrexone, which blocks opioid receptors. It can interfere with opioid pain medicines and can precipitate withdrawal in an opioid-dependent patient. Patients should disclose prescribed, nonprescribed, and opioid-use-disorder medicines and coordinate planned procedures or pain care rather than changing opioid timing on their own.

Is Foundayo an antidepressant or stimulant?

No. Foundayo contains orforglipron, a GLP-1 receptor agonist. Contrave contains naltrexone plus bupropion, an antidepressant component. Both may affect appetite, but that shared outcome does not make their mechanisms or safety screens the same.

Who should not use Foundayo?

The current label contraindicates Foundayo for people with a personal or family history of medullary thyroid carcinoma, MEN 2, or serious hypersensitivity to orforglipron or product ingredients. Pregnancy, severe GI disease, pancreatitis or gallbladder history, dehydration risk, diabetes medicines, diabetic eye disease, oral contraception, and planned procedures also require product-specific review.

Who should not use Contrave?

The current label lists contraindications that include uncontrolled hypertension, seizure disorder, current or prior bulimia or anorexia nervosa, use of another bupropion-containing product, chronic opioid use or acute opioid withdrawal, certain abrupt alcohol or sedative discontinuation, recent MAOI use, and allergy to product ingredients. A clinician should check the complete current label and patient history.

Is compounded or generic orforglipron the same as Foundayo?

No seller should present a compounded, research-use, imported, counterfeit, or supplement product as FDA-approved Foundayo. Verify the active ingredient, manufacturer, intact labeled packaging, prescription, dispensing pathway, adverse-event contact, and follow-up. Compounded medicines are not FDA-approved finished drug products.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Foundayo (orforglipron) current prescribing information DailyMed: Contrave (naltrexone and bupropion) prescribing information MedlinePlus: Naltrexone and bupropion patient information PubMed: ATTAIN-1 phase 3 trial of orforglipron in adults with obesity ClinicalTrials.gov: NCT05869903 ATTAIN-1 orforglipron study FDA: Concerns with unapproved GLP-1 drugs used for weight loss Peptide12: Orforglipron side effects Peptide12: Orforglipron vs phentermine Peptide12: Orforglipron vs Qsymia Peptide12: Wegovy vs Contrave Peptide12: Zepbound vs Contrave Peptide12: Tirzepatide vs Contrave Peptide12: Semaglutide vs Contrave Peptide12: Fake GLP-1 online pharmacy checklist Peptide12: How online peptide therapy works